Evidenzbasierte Schwindeltherapie

ZUSAMMENFASSUNG

Das Ziel der vorliegenden Metaanalyse war es, die Wirksamkeit und Sicherheit der Fixkombination aus Cinnarizin 20 mg und Dimenhydrinat 40 mg im Vergleich zu anderen Antivertiginosa bei Patienten mit zentralem und/oder peripherem vestibulärem Schwindel zu untersuchen. Hierzu wurden die individuellen Patientendaten von 4 randomisierten, doppelblinden, kontrollierten klinischen Studien mit nahezu identischem Studiendesign, zusammengeführt. Insgesamt wurden die Daten von 795 Patienten mit Schwindel verschiedener Genese (zentral- und/oder peripher-vestibulär) in die Analyse einbezogen.

In allen 4 Studien wurden die Patienten 4 Wochen mit der Testmedikation (Fixkombination aus Cinnarizin 20 mg und Dimenhydrinat 40 mg), mit verschiedenen Vergleichsmedikationen (Cinnarizin 20 mg, 50 mg, Dimenhydrinat 40 mg, 100 mg, Betahistin-Dimesilat 12 mg, Betahistin-Dihydrochlorid 16 mg) oder einem Placebo behandelt. Als Hauptzielkriterium der Metaanalyse diente die Veränderung der Schwindelsymptomatik nach 4-wöchiger Behandlung. Die subjektiven Schwindelbeschwerden der Patienten wurden mit Hilfe eines validierten Schwindel-Scores (mittlerer Vertigo Score, MVS) ermittelt. Die Nebenzielkriterien umfassten verschiedene Ansprechraten, die Veränderung der vegetativen Begleitsymptomatik und die Beurteilung der Wirksamkeit und Verträglichkeit durch Untersucher und Patienten.

Zusammenfassend deuten die Ergebnisse der vorliegenden Metaanalyse darauf hin, dass die Fixkombination aus Cinnarizin 20 mg und Dimenhydrinat 40 mg bei zentralem und/oder peripherem Schwindel eine potenziell überlegene Behandlungsoption mit besserer Wirksamkeit im Vergleich zu anderen Antivertiginosa bei gleichzeitig guter Verträglichkeit ist.

ABSTRACT

The aim of the present meta-analysis was to evaluate the efficacy and safety of the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg in comparison with various other antivertigo treatments in patients with central and/or peripheral vestibular vertigo. For this purpose, individual patient data from 4 randomised, double-blind, controlled clinical trials with almost identical study design were pooled. In total, the data of 795 patients with vertigo of different origin (central and/or peripheral-vestibular) were included in the analysis. In all 4 included studies, patients were treated for 4 weeks with the test medication (fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg), with different comparators (cinnarizine 20 mg, 50 mg, dimenhydrinate 40 mg, 100 mg, betahistine dimesylate 12 mg, betahistine dihydrochloride 16 mg) or a placebo. The main outcome of the meta-analysis was the change in vertigo symptoms after 4 weeks of treatment. Patients’ subjective vertigo symptoms were assessed using a validated vertigo score (Mean Vertigo Score, MVS). Secondary outcome measures included various response rates, change in concomitant vegetative symptoms and investigator and patient ratings of efficacy and tolerability.

In summary, the results of the present meta-analysis suggest that the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg is a potentially superior treatment option for central and/or peripheral vertigo, with significantly better efficacy compared to other antivertigo treatments while being well tolerated.

Schlüsselwörter

Metaanalyse - evidenzbasiert - Pharmakotherapie - Schwindel - Cinnarizin - Dimenhydrinat

Key words

Meta-analysis - evidence-based - pharmacotherapy - vertigo - cinnarizin - dimenhydrinat

Publication History

Article published online:
11 November 2022

• Literatur

• 1 Brandt T. Vertigo: its multisensory syndromes. Berlin: Springer Science & Business Media; 2013
• 2 Davis A, Moorjani P. The epidemiology of hearing and balance disorders. Textbook of audiological medicine 2003: 89-99
• 3 Teggi R, Manfrin M, Balzanelli C. et al Point prevalence of vertigo and dizziness in a sample of 2672 subjects and correlation with headaches. Acta Otorhinolaryngologica Italica 2016; 36 (03) 215
• 4 Luxon LM. Evaluation and management of the dizzy patient. Journal of Neurology, Neurosurgery & Psychiatry 2004; 75: iv45-iv52
• 5 Corrales CE, Bhattacharyya N. Dizziness and death: An imbalance in mortality. Laryngoscope 2016; 126: 2134-2136
• 6 Mira E. Improving the quality of life in patients with vestibular disorders: the role of medical treatments and physical rehabilitation. International journal of clinical practice 2008; 62: 109-114
• 7 Honrubia V, Bell TS, Harris MR. et al Quantitative evaluation of dizziness characteristics and impact on quality of life. Am J Otol 1996; 17: 595-602
• 8 Smith DB.. Dizziness: The history and physical examination. Dizziness and Balance Disorders. In: Kaufmann, Arenberg (eds.). Amsterdam: Kugler Publisjer; 1993: 3-10
• 9 Schuller DE, Schleuning AJ, DeWeese DD. et al DeWeese and Saunders’ Otolaryngology – head and Neck Surgery. London: Mosby Incorporated; 1994: 495-513
• 10 Brandt T, Dieterich M, Strupp M. Vertigo and dizziness – common complaints. Berlin: Springer; 2013
• 11 Arab SF, Düwel P, Jüngling E. et al Inhibition of voltage-gated calcium currents in type II vestibular hair cells by cinnarizine. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 570-575
• 12 Düwel P, Haasler T, Jüngling E. et al Effects of cinnarizine on calcium and pressure-dependent potassium currents in guinea pig vestibular hair cells. Naunyn-Schmiedeberg’s Arch Pharmacol 2005; 371: 441-448
• 13 Soto E, Vega R. Neuropharmacology of vestibular system disorders. Curr Neuropharmacol 2010; 08 (01) 26-40
• 14 Lacour M. Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. J Vestib Res 2013; 23: 139-151
• 15 Pytel J, Nagy G, Toth A. et al Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: A 4-week, randomized, double-blind, active- and placebo-controlled, parallel-group, outpatient study. Clin Ther 2007; 29 (01) 84-98
• 16 Hahn A, Novotný M, Shotekov PM. et al Comparison of cinnarizine/dimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins. Clin Drug Investig 2011; 31 (06) 371-83
• 17 Cirek Z, Schwarz M, Baumann W. et al Efficacy and tolerability of a fixed combination of cinnarizine and dimenhydrinate versus betahistine in the treatment of otogenic vertigo. A double-blind, randomized clinical study. Clin Drug Investig 2005; 25: 377-89
• 18 Scholtz AW, Hahn A, Stefflova B. et al Efficacy and Safety of a Fixed Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg vs Betahistine Dihydrochloride 16 mg in Patients with Peripheral Vestibular Vertigo: A Prospective, Multinational, Multicenter, Double-Blind, Randomized, Non-inferiority Clinical Trial. Clin Drug Investig 2019; 39: 1045-1056
• 19 Otto V, Fischer B, Schwarz M. et al Treatment of vertebrobasilar insufficiency-associated vertigo with a fixed combination of cinnarizine and dimenhydrinate. Int Tinnitus J 2008; 14: 57-67
• 20 Hahn A, Sejna I, Stefflova B. et al A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders. A randomized, reference-controlled, clinical study. Clin Drug Investig 2008; 28: 89-99
• 21 Scholtz AW, Schwarz M, Baumann W. et al Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study. Clin Ther 2004; 26: 866-77
• 22 Scholtz AW, Steindl R, Burchardi N. et al Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis. A randomized, double-blind, non-inferiority study. Clin Drug Investig 2012; 32 (06) 387-99
• 23 Novotný M, Kostrica R. Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Menière’s disease: a randomized, double-blind, parallel-group clinical study. Int Tinnitus J 2002; 08: 115-23
• 24 Kessler L, Bognar-Steinberg I, Baumann W. et al Treatment of vestibular vertigo: comparison of a fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg with the 2.5-fold higher dosed active drugs in monotherapy. A prospective, randomized, reference-controlled, two-center, double-blind study. Arch Sensol Neurootol Sci Pract 2012; 07: 1-13
• 25 Scholtz AW, Waldfahrer F, Hampel R. et al Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials. Clin Drug Investig 2022
• 26 Rahlfs VW, Zimmermann H. The Mean Vertigo Score (MVS) Outcome Scale and Its Use in Clinical Research for Quantifying Vestibular Disorders. Frontiers in Neurology 2021; 12: 601749